TTX-MC138 Takes Aim at a Master MicroRNA

Most cancer drugs attack something on the tumour cell: a receptor, an enzyme, a signalling pathway or a surface protein.
TTX-MC138 takes a different approach. It is designed to inhibit microRNA-10b (miR-10b), a small regulatory RNA strongly associated with invasion, metastatic progression and survival of metastatic tumour cells.

The idea is unusually ambitious: rather than targeting one cancer type, TTX-MC138 tries to interfere with a biological programme that helps cancer cells become and remain metastatic. miR-10b can suppress genes involved in limiting invasion and differentiation, including HOXD10, while promoting migration, stem-like behaviour and metastatic survival.
In several preclinical models, blocking miR-10b did more than slow the formation of new metastases: established metastatic lesions regressed, particularly when miR-10b inhibition was combined with chemotherapy.
TTX-MC138 delivers an anti-miR-10b oligonucleotide using iron-oxide nanoparticles. Earlier human microdosing work showed that the drug could reach metastatic lesions in the bone, lung and liver and produce substantial suppression of its molecular target, addressing one of the biggest challenges in RNA therapeutics: actually getting the drug into tumour tissue.

The first-in-human phase 1a trial has now produced an early clinical signal. Among 14 efficacy-evaluable patients with heavily pretreated advanced solid tumours, 10 (71.4%) achieved stable disease as their best response. Disease control persisted in 57.1% at three months and 35.7% at six months, while three patients remained progression-free at one year. No dose-limiting toxicities were reported across the tested doses, including the highest dose of 4.8 mg/kg.

These numbers should be interpreted cautiously. The trial was small, heterogeneous and designed primarily to establish safety, not efficacy. There was no control group, and stable disease alone does not prove that TTX-MC138 was responsible for the prolonged disease control. Still, the pattern is interesting because the drug is not expected to behave like a conventional cytotoxic agent that rapidly shrinks tumours. Its proposed role is to disrupt the metastatic state itself.

Exploratory blood RNA sequencing adds another layer. Treatment was associated with increased antitumour cytokine activity, cytotoxic immune signalling and inflammatory monocyte programmes, while patients with stable disease showed stronger cytotoxic and type-I interferon signatures. These findings are preliminary, but they suggest that miR-10b inhibition may influence not only tumour-cell behaviour but also the immune environment surrounding the disease.

There are reasons why this concept could eventually matter in prostate cancer. Advanced prostate cancer can become increasingly plastic, invasive and less dependent on the androgen receptor, while bone metastases remain a defining feature of the disease. If a subset of metastatic prostate cancers also becomes dependent on miR-10b-driven survival programmes, the relevant biomarker may ultimately be miR-10b expression rather than tumour type itself.

Source.